Neoehrlichiosis Causing Hemolytic Anemia in Patients Treated with Rituximab, Norway, 2024-2025.

Emerg Infect DisSep 1, 2026
Case ReportHematologyInfectious Diseases

Martin Paulson, Christine Wennerås, Hanne Quarsten et al.

✦ AI-curated · Sources linked

Case in brief

Three rituximab-treated patients in Norway presented with direct antiglobulin test-negative hemolytic anemia due to Neoehrlichia mikurensis infection. Symptoms included splenomegaly and night sweats, with hemolysis severity varying from mild to severe, necessitating transfusions and splenectomy in one case. All patients achieved complete resolution of symptoms following a 21-day doxycycline treatment.

Diagnostic / clinical pearl

Neoehrlichiosis should be considered as a potential cause of hemolytic anemia in patients treated with rituximab, especially in endemic regions.

Source

PubMed · PMID 42660584

Published in Emerg Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.